Lundbeck and partner present "slam-dunk" data for new Alzheimer's drug

Analysts are excited about Lundbeck’s final data presentation for Rexulti, which has reached all endpoints in a phase III study.
Photo: Jens Dresling
Photo: Jens Dresling
by christian bundgaard, translated by catherine brett

The new data that Lundbeck and Otsuka have released on their Alzheimer’s candidate Rexulti has eliminated any doubt about the treatment’s potential, Danish financial daily Børsen writes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading